Inhibikase Therapeutics CEO Milton Werner's 2022 pay jumps 22% to $744K
Inhibikase Therapeutics reports 2022 executive compensation
By ExecPay News
Published: May 5, 2023
Inhibikase Therapeutics reported fiscal year 2022 executive compensation information on May 5, 2023.
In 2022, two executives at Inhibikase Therapeutics received on average a compensation package of $659K, a 20% increase compared to previous year.
Average pay of disclosed executives at Inhibikase Therapeutics
Milton H. Werner, Chief Executive Officer, received $744K in total, which increased by 22% compared to 2021. 67% of Werner's compensation, or $501K, was in salary. Werner also received $140K in non-equity incentive plan, $86K in option awards, as well as $17K in other compensation.
Joseph Frattaroli, Chief Financial Officer, received a compensation package of $575K, which increased by 18% compared to previous year. 69% of the compensation package, or $396K, was in salary.
Related executives
You may also like
Source: SEC filing on May 5, 2023.